Abstract 705P
Background
Typical entry criteria in early phase studies include expected life expectancy greater than 3 months. However, this evaluation is quite subjective and more objective and reproducible tools are needed to improve patient selection for phase I trials. The quantification of ctDNA shed by measuring tumor fraction (TF) has been associated with prognosis in patients with solid tumors. Our objective was to develop and validate a nomogram integrating TF to predict overall survival in cancer patients referred for early phase studies.
Methods
All consecutive adult patients with an advanced solid tumor included between December 2020 and December 2021 in two precision medicine studies (BIP, NCT02534649, sponsor: Institut Bergonié, Bordeaux, France) and STING (NCT04932525, sponsor: Institut Gustave Roussy, Villejuif, France). All patients underwent comprehensive genomic profiling with the 324-gene FoundationOne®. TF was analyzed as a binary variable, indicating whether a specimen had TF ≥10% or TF <10%. Other variables included previously validated prognostic scores such as the Royal Marsden (RMHs: albumin, LDH, number of metastatic sites ) and the GRIm (LDH, neutrophil/lymphocyte ratio, albumin) scores as well as their individual components.
Results
TF > 10, the GRIM score and the RMH score were independent prognostic factors in the training dataset (BIP study n= 965 patients). We generated a nomogram based on TF, number of metastatic sites, albumine level and neutrophil/lymphocyte ratio. To determine the clinical usefulness of our nomogram, we compared it with the RMH and GRIM scores. For our nomogram, the area under the receiver operating characteristic curve (AUC) was 0.79 as compared with 0.65 and 0.68 for the RMH and GRIM scores respectively. In the validation dataset (STING study, n= 947), the AUC was 0.76 as compared with 0.60 and 0.64 for for the RMH and GRIM scores respectively. The nomogram was well-calibrated in both the training and validation datasets.
Conclusions
This is the first prospective analysis confirming that TF is a strong prognostic factor in patients with advanced solid tumors. The TIMES nomogram represent an helpful tool in the process of patient selection for phase I trial entry.
Clinical trial identification
NCT02534649; NCT04932525.
Editorial acknowledgement
Legal entity responsible for the study
Institut Bergonié.
Funding
Fondation Bergonié, Fondation Gustave Roussy.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
678P - ExoDS: A bioengineered exosome-based capsule for targeted delivery of chemotherapy drugs to cancer cells and cancer stem cells
Presenter: Abhishek Dutta
Session: Poster session 17
679P - Lurbinectedin (LRB) pharmacokinetics (PK) and safety when co-administered with itraconazole (ITZ) in patients with advanced solid tumor
Presenter: Irene Moreno
Session: Poster session 17
680P - First results from the phase I trial of the ATR inhibitor, ART0380, in advanced solid tumors
Presenter: Kathleen Moore
Session: Poster session 17
681P - First-in-human study of ATR inhibitor IMP9064 monotherapy and in combination with PARP inhibitor senaparib in patients with advanced solid tumors
Presenter: Chia-Chi Lin
Session: Poster session 17
683P - Preclinical evaluation of HLX42, a novel EGFR-targeting ADC, for cetuximab or TKI resistant cancer
Presenter: Yongqiang Shan
Session: Poster session 17
684P - Phase I trial of SHR-A1811 in HER2-expressing advanced gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJ) and colorectal cancer (CRC)
Presenter: Jin Li
Session: Poster session 17
685P - BL-M07D1, a HER2 antibody-drug conjugate in subjects with locally advanced or metastatic HER2 expressing breast cancer and other solid tumors
Presenter: Erwei Song
Session: Poster session 17
686P - Phase I study of HRS8807, an oral selective ER covalent antagonist (SERCA), in ER+/HER2- locally advanced (LA) or metastatic (M) breast cancer (BC)
Presenter: Jiong Wu
Session: Poster session 17
687P - A CRUK phase I/IIA, first in human dose-escalation and expansion trial of HMBD-001 (an anti-HER3 antibody) in patients with advanced HER3 positive solid tumours
Presenter: Johann de Bono
Session: Poster session 17
688P - Pharmacokinetics of HMBD-001, a human monoclonal antibody targeting HER3, a CRUK first-in-human phase I trial in patients with advanced solid tumours
Presenter: Oladipo Idowu
Session: Poster session 17